US Patent

US8513263 — Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors

Composition of Matter · Assigned to Array Biopharma Inc · Expires 2029-12-23 · 4y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of compounds that inhibit Trk kinases and can be used to treat diseases that can be treated with a Trk kinase inhibitor.

USPTO Abstract

Compounds of Formula (I) in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
US8513263
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-12-23
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.